Non-biological complex drugs and their analogues in the pathogenetic therapy of multiple sclerosis: Issues of efficacy and safety in clinical use
| Autor: | I. D. Stolyarov, A. M. Petrov, M. V. Votintseva, I. G. Nikiforova |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2015 |
| Předmět: | |
| Zdroj: | Неврология, нейропсихиатрия, психосоматика, Vol 7, Iss 1, Pp 75-79 (2015) |
| Druh dokumentu: | article |
| ISSN: | 2074-2711 2310-1342 |
| DOI: | 10.14412/2074-2711-2015-1-75-79 |
| Popis: | The paper generalizes the experience with one of the main original drugs for the treatment of multiple sclerosis (MS) – glatiramer acetate (GA, Copaxone®, Teva) in large Russian MS centers. The performed analysis of clinical trials suggests the high efficacy and favorable safety profile of the drug. The fact that patents for a number of effective and widely used original drugs, including those for agents from a group of immunomodulators, used to treat MS expire is one of the features of the current development of medicine. Due to the fact that most of them belong to interferons-β, i.e. biologicals, or structurally close to nonbiological complex drugs, the authors discuss the need to conduct comparative clinical trials of the original drug and follow-on glatiramoids with measured endpoints that can be used to establish their efficacy, safety, and evidence for therapeutic equivalence in order to examine their potential interchangeability. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|